Source: MIL-OSI Submissions
The largest of Aroa’s wound care products, the 8.5 by 6-inch device has been launched in the United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system.
Aroa Chief Executive, Brian Ward said this large format version of Endoform® Natural addresses the growing need to treat large wounds with a single sheet of their extracellular matrix-based product and provides more options for clinicians.
“We saw a need to offer Healthcare Providers a simple option for larger and often more difficult-to- treat wounds arising from trauma and complications from surgical wounds, or other diseases where healing is impaired. This format is also suitable for wounds such as chronic wounds and venous leg ulcers.
“We are also seeing that Endoform® Natural is increasingly being used in conjunction with negative pressure wound therapy, and this large format will be particularly useful in these treatment applications.”
Aroa intends to make the large format available in a range of global markets as and when regulatory approvals are granted.
“Aroa is committed to having solutions for a wide variety of wounds and wound sizes, and to partnering with clinicians to ensure there are effective solutions for patients presenting with an array of challenging wounds,” says Brian Ward.
About Aroa Biosurgery:
Aroa headquartered in Auckland, New Zealand is a private, venture-funded soft-tissue repair company that develops and manufactures medical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from their Endoform® platform, a novel extracellular matrix biomaterial and distributed in the United States by Appulse and Tela Bio. Aroa strives to improve patient outcomes and provide better healing, every day, everywhere for everybody. www.aroabio.com/